This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Alpha - synuclein in Parkinson's disease (PD)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Alpha-Synuclein in Parkinson's disease

  • alpha Synuclein is a presynaptic neuronal protein that is linked genetically and neuropathologically to Parkinson's disease (PD)

  • deposition of alpha Synuclein and neuronal injury occur many years before the canonical motor signs emerges

  • evidence shows that alpha - synuclein seed amplification assays (SAAs) have the potential to differentiate people with PD from healthy controls
    • results show that the assay classifies people with Parkinson's disease with high sensitivity and specificity (3)

Reference:

  • Stefanis L. alpha-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med. 2012 Feb;2(2):a009399. doi: 10.1101/cshperspect.a009399. PMID: 22355802; PMCID: PMC3281589.
  • Russo MJ et al.High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease. Acta Neuropathol Commun. 2021 Nov 6;9(1):179. doi: 10.1186/s40478-021-01282-8
  • Siderowf A et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using alpha-synuclein seed amplification: a cross-sectional study. Lancet Neurology May 2023

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.